Mural Oncology (NASDAQ:MURA) Stock Rating Lowered by Raymond James

Mural Oncology (NASDAQ:MURA) was downgraded by analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a research report issued on Tuesday, Marketbeat Ratings reports. They currently have a $18.00 price target on the stock.

Several other analysts have also weighed in on MURA. Jones Trading restated a “hold” rating on shares of Mural Oncology in a report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Stock Down 9.5 %

Shares of NASDAQ MURA opened at $1.33 on Tuesday. The firm’s 50-day simple moving average is $3.82 and its 200 day simple moving average is $3.60. The stock has a market cap of $22.91 million, a P/E ratio of -0.15 and a beta of 3.66. Mural Oncology has a fifty-two week low of $1.30 and a fifty-two week high of $5.12.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the company posted ($3.57) EPS. On average, sell-side analysts anticipate that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mural Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. Acorn Capital Advisors LLC acquired a new position in shares of Mural Oncology in the 4th quarter worth $4,141,000. Renaissance Technologies LLC boosted its position in shares of Mural Oncology by 17.4% in the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock valued at $768,000 after purchasing an additional 35,403 shares during the period. Geode Capital Management LLC increased its stake in Mural Oncology by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after purchasing an additional 4,731 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Mural Oncology by 1.4% during the 4th quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after buying an additional 2,470 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in Mural Oncology during the third quarter valued at about $340,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.